Mia's Feed
Medical News & Research

Intravenous Tenecteplase Enhances Outcomes Before Thrombectomy in Stroke Patients

Intravenous Tenecteplase Enhances Outcomes Before Thrombectomy in Stroke Patients

Share this article

A recent study reveals that administering intravenous tenecteplase before endovascular thrombectomy can significantly improve functional independence in stroke patients, highlighting advances in stroke treatment protocols.

2 min read

Recent research published in the New England Journal of Medicine highlights the benefits of administering intravenous tenecteplase prior to endovascular thrombectomy in patients experiencing acute ischemic stroke caused by large-vessel occlusion. The study, conducted by Dr. Zhongming Qiu and colleagues in China, investigated whether adding tenecteplase could improve functional outcomes. Involving 550 patients presenting within 4.5 hours of stroke onset, the trial compared two groups: one receiving tenecteplase followed by thrombectomy, and another undergoing thrombectomy alone.

Results showed that 52.9% of patients who received tenecteplase achieved functional independence at 90 days, compared to 44.1% in the thrombectomy-only group. Early reperfusion was more successful in the tenecteplase group, with 6.1% achieving reperfusion before thrombectomy versus 1.1% in the control group. Post-procedure outcomes indicated similar rates of successful reperfusion after thrombectomy in both groups. Although symptomatic intracranial hemorrhage was slightly higher in the tenecteplase group (8.5% vs. 6.7%), mortality rates at 90 days were comparable (22.3% vs. 19.9%). The authors note that while the primary outcome favors tenecteplase, secondary outcomes were less conclusive, warranting further investigation.

This study suggests that adding tenecteplase to the treatment protocol for eligible stroke patients can potentially improve long-term functional recovery, emphasizing the importance of timely intervention. The findings were supported by funding from China Shijiazhuang Pharmaceutical Company Recomgen Pharmaceutical, and the research aligns with ongoing efforts to optimize stroke management strategies.

Source: https://medicalxpress.com/news/2025-05-intravenous-tenecteplase-beneficial-endovascular-thrombectomy.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

New Insights into the Visual Thalamus: Beyond a Simple Relay in Brain's Visual Processing

Recent research reveals that the visual thalamus plays an active role in processing and reshaping visual signals, going beyond its traditional role as a simple relay station. The study highlights the integration of inputs from other brain regions, especially the superior colliculus, to enhance motion detection and visual perception.

US Sees Highest Measles Cases in 33 Years Driven by Texas Outbreak

The United States reports its highest measles case count in 33 years in 2025, driven largely by an outbreak in Texas. Experts warn that low vaccination rates and vaccine hesitancy threaten to cause further outbreaks nationwide. Learn more about this alarming trend and its implications for public health.

Understanding Long COVID: The Impact of Varying Definitions on Prevalence Estimates

Varying definitions of long COVID across studies lead to wide estimates of prevalence, complicating diagnosis and research efforts. A recent UCLA study highlights the urgent need for a standardized definition to improve patient care and scientific understanding.

Effectiveness of Two-Dose Zoster Vaccine in Preventing Herpes Zoster Ophthalmicus and Cardiovascular Events

A new study shows that two doses of recombinant zoster vaccine significantly reduce the risk of herpes zoster ophthalmicus and cardiovascular events in adults aged 50 and older, highlighting additional health benefits of vaccination.